Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease
Sponsor: Ain Shams University
Summary
The goal of this clinical trial is to evaluate whether dapagliflozin can reduce the risk of worsening kidney function or death from cardiovascular or renal causes in adults with advanced chronic kidney disease (CKD), with or without type 2 diabetes. The main questions it aims to answer are: 1. Does dapagliflozin reduce the rate of decline in kidney function or progression to end-stage kidney disease in adults with advanced CKD? 2. Does dapagliflozin reduce the risk of death from cardiovascular or renal causes in patients with advanced CKD? Researchers will compare dapagliflozin to a placebo to see if dapagliflozin improves kidney and cardiovascular outcomes in this high-risk population.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-05-01
Completion Date
2026-11-01
Last Updated
2025-05-21
Healthy Volunteers
No
Interventions
Dapagliflozin 10 mg
Dapagliflozin 10 mg will be added in addition to standard of care
Locations (1)
Ain Shams University Hospitals
Cairo, Egypt